Related references
Note: Only part of the references are listed.A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Dong Pan et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
OA07.06 Interdependence of KRAS and TP53 Mutations in Predicting ICI Efficacy in EGFR/ALKWT Non-Squamous NSCLC: Results From 1129 Patient-Level Data
X. Li et al.
Journal of Thoracic Oncology (2021)
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen et al.
NATURE GENETICS (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Kai Zhang et al.
CLINICAL CANCER RESEARCH (2020)
Impact of STK11 and KRAS co-mutations on outcomes with immunotherapy in non-small cell lung cancer.
Fahmin Basher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Michael A. Gillette et al.
CELL (2020)
Integrative Proteomic Characterization of Human Lung Adenocarcinoma
Jun-Yu Xu et al.
CELL (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
Discordant genomic correlates of PD-L1 expression in lung adenocarcinoma among multiple cohorts using dissimilar PD-L1 testing techniques
X. Jiao et al.
ANNALS OF ONCOLOGY (2020)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer
Wenfeng Fang et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
M. Garassino et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Proteogenomic landscape of squamous cell lung cancer
Paul A. Stewart et al.
NATURE COMMUNICATIONS (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
Rahul Nahar et al.
NATURE COMMUNICATIONS (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Diana Miao et al.
NATURE GENETICS (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
Kathryn C. Arbour et al.
CLINICAL CANCER RESEARCH (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Youngtae Jeong et al.
CANCER DISCOVERY (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2015)
Computational procedures for probing interactions in OLS and logistic regression: SPSS and SAS implementations
Andrew F. Hayes et al.
BEHAVIOR RESEARCH METHODS (2009)
Statistics Notes - Interaction revisited: the difference between two estimates
DG Altman et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
